Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function

Research output: Contribution to journalArticle

14 Scopus citations


Cord blood (CB) transplantation has been used over the last 24 years to treat patients with malignant and nonmalignant disorders. CB has its advantages and disadvantages compared with other sources of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) for transplantation. More knowledge of the cytokines and intracellular signaling molecules regulating HSCs and HPCs could be used to modulate these regulators for clinical benefit. This review provides information about the general field of CB transplantation and about studies from the author's laboratory that focus on regulation of HSCs and HPCs by CD26/DPPIV, SDF-1/CXCL12, the Rheb2-mTOR pathway, SIRT1, DEK, cyclin-dependent kinase inhibitors, and cytokines/growth factors. Cryopreservation of CB HSCs and HPCs is also briefly discussed.

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalAnnals of the New York Academy of Sciences
Issue number1
StatePublished - Aug 2012



  • Cord blood
  • Cytokines
  • Intracellular signals
  • Stem and progenitor cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this